ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Govindan on the Potential for Alectinib

Ramaswamy Govindan, MD
Published: Friday, Oct 31, 2014

Ramaswamy Govindan, MD, Director, Thoracic Oncology, Co-Director, Section of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the potential for the ALK inhibitor alectinib.

Crizotinib and ceritinib are approved in the US and have demonstated 50-60% response rates in patients with ALK-positive non-small cell lung cancer (NSCLC). In a small study in Japan, alectinib elicited a 93% response rate, median survival of 27 months, and activity against brain metastases. Studies in the US are being conducted now comparing crizotinib and alectinib.

There remains a need to understand resistance, and mechanisms of resistance, of these 3 agents. The question also remains as to whether ALK-positive patients should be stratified.

<<< View more from the 2014 Multidisciplinary Symposium in Thoracic Oncology

Ramaswamy Govindan, MD, Director, Thoracic Oncology, Co-Director, Section of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the potential for the ALK inhibitor alectinib.

Crizotinib and ceritinib are approved in the US and have demonstated 50-60% response rates in patients with ALK-positive non-small cell lung cancer (NSCLC). In a small study in Japan, alectinib elicited a 93% response rate, median survival of 27 months, and activity against brain metastases. Studies in the US are being conducted now comparing crizotinib and alectinib.

There remains a need to understand resistance, and mechanisms of resistance, of these 3 agents. The question also remains as to whether ALK-positive patients should be stratified.

<<< View more from the 2014 Multidisciplinary Symposium in Thoracic Oncology




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x